Celica Biomedical

Celica Biomedical is a privately held, pre-revenue Slovenian research institute founded in 2000, specializing in neuroscience (particularly astrocyte biology) and oncology immunotherapies. The company leverages a deep scientific foundation in regulated exocytosis and cell physiology to develop novel treatment strategies for CNS disorders and cancer vaccines. It operates a quality-managed laboratory, secures public research funding, and collaborates internationally, positioning itself to bridge the gap between academic discovery and clinical application.

Proprietary technology for monitoring regulated exocytosis at the single-cell level, originating from the Cambridge-NARIP® project. Applied to study astrocyte physiology (vesicle mobility, fusion pores, gliotransmission) and to develop dendritic cell-based cancer vaccines. Supported by in-house super-resolution microscopy.

In neuroscience, Celica competes with large pharma and biotechs exploring neuroinflammation and glial targets, but its deep, specialized focus on astrocyte exocytosis is a differentiator. In cancer vaccines, it faces competition from more advanced cellular immunotherapy companies and platforms (e.g., mRNA vaccines, neoantigen targeting), where demonstrating superior efficacy or a unique mechanism will be critical.